Adoptive T cell therapy for the treatment of viral infections.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

1. A Phase I Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against BK-Virus in Adult Kidney Transplant Recipients.Journal of medical virology · 2025
   Article
2. Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022
   Article
3. High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?Journal of translational medicine · 2020
   Article
4. Infectious disease risks in pediatric renal transplantation.Pediatric nephrology (Berlin, Germany) · 2019
   Review
5. A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells.Scientific reports · 2018
   Article
6. Intestinal Adenovirus Shedding Before Allogeneic Stem Cell Transplantation Is a Risk Factor for Invasive Infection Post-transplant.EBioMedicine · 2018
   Article
7. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.Nature communications · 2017
   Article
8. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.Blood · 2016
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.